Phase
Condition
Ulcers
Gastrointestinal Diseases And Disorders
Hemorrhage
Treatment
UI-EWD
Conventional therapy
Clinical Study ID
Ages > 22 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adults age 22 years or older
Presentation with acute overt gastrointestinal bleeding (hematemesis, melena, and/orhematochezia)
Subject voluntarily agrees to participate in the clinical investigation, provideswritten informed consent, and will be able to comply with the investigationalprotocol in the opinion of the site investigator
Cause of bleeding as determined at upper endoscopy is one of the following sources:a gastric or duodenal ulcer with active bleeding (spurting or oozing) or anon-bleeding visible vessel; an esophageal, gastric or duodenal tumor with activebleeding or a non-bleeding visible vessel; a gastric or duodenal Dieulafoy lesionwith active bleeding or a non-bleeding visible vessel; or an actively bleedingMallory-Weiss tear. The definition of "active oozing" will require bleeding topersist for ≥ 3 minutes of endoscopic observation.
Exclusion
Exclusion Criteria:
Incarceration
Subjects that are not able to provide written informed consent
Pregnancy or nursing mothers
Endoscopic hemostatic treatment in the past 30 days
Use of triple antithrombotic therapy at the time of presentation
Subjects who underwent gastric or duodenal endoscopic mucosal resection (EMR) orendoscopic submucosal dissection (ESD) procedures within the past 2 months
Post-polypectomy bleeding
Subjects with erosive esophagitis, erosive gastritis, esophageal ulcer, or vascularectasia including gastric antral vascular ectasia
Platelet count < 50 x 10^9/L
INR > 3.5 (or prothrombin time >35 seconds in patient not on warfarin and onlyprothrombin time is provided by local lab), at time of procedure or closest toprocedure time
Subjects who have documented galactose intolerance, Lapp lactase deficiency orglucose-galactose malabsorption
Subjects with documented hypersensitivity to Brilliant Blue FCF
Subjects with suspected bowel obstruction or gastrointestinal fistulas, and thosesuspected or are at high risk of having gastrointestinal perforation.
Endoscopy not performed within 36 hours of presentation to hospital/emergencydepartment
Study Design
Study Description
Connect with a study center
McGill University
Montréal, Quebec
CanadaActive - Recruiting
St. Michael's Hospital
Toronto,
CanadaSite Not Available
Vancouver General Hospital
Vancouver,
CanadaActive - Recruiting
Copenhagen University Hospital
Hvidovre,
DenmarkActive - Recruiting
Odense University Hospital
Odense,
DenmarkSite Not Available
St. Antoine
Paris,
FranceActive - Recruiting
Emek Medical Center
Afula,
IsraelActive - Recruiting
Cleveland Clinic London
London,
United KingdomActive - Recruiting
University of Alabama
Birmingham, Alabama 35205
United StatesActive - Recruiting
Yale
New Haven, Connecticut 06520
United StatesActive - Recruiting
RUSH University
Chicago, Illinois 60612
United StatesActive - Recruiting
Brigham and Women's Hospital
Boston, Massachusetts 02115
United StatesActive - Recruiting
Rutgers University
Piscataway, New Jersey 08901
United StatesActive - Recruiting
Northwell Health
Manhasset, New York 11030
United StatesActive - Recruiting
NYU Langone
New York, New York 10016
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.